Orthopaedic Research and Biotechnology, The Children's Hospital, Westmead, Australia.
Bone. 2010 Mar;46(3):852-9. doi: 10.1016/j.bone.2009.11.009. Epub 2009 Nov 14.
Intermittent Parathyroid Hormone (PTH)((1-34)) has an established place in osteoporosis treatment, but also shows promising results in models of bone repair. Previous studies have been dominated by closed fracture models, where union is certain. One of the major clinical needs for anabolic therapies is the treatment of open and high energy fractures at risk of non-union. In the present study we therefore compared PTH((1-34)) treatment in models of both open and closed fractures. 108 male Wistar rats were randomly assigned to undergo standardized closed fractures or open osteotomies with periosteal stripping. 27 rats in each group were treated s.c. with PTH((1-34)) at a dose of 50 mug/kg 5 days a week, the other 27 receiving saline. Specimens were harvested at 6 weeks for mechanical testing (n=17) or histological analysis (n=10). In closed fractures, union by any definition was 100% in both PTH((1-34)) and saline groups at 6 weeks. In open fractures, the union rate was significantly lower (p<0.05), regardless of treatment. In open fractures the mechanically defined union rate was 10/16 (63%) in saline and 11/17 (65%) in PTH((1-34)) treated fractures. By histology, the union rate was 3/9 (33%) with saline and 5/10 (50%) with PTH((1-34)). Radiological union was seen in 13/25 (52%) for saline and 15/26 (58%) with PTH((1-34)). Open fractures were associated with decreases in bone mineral content (BMC) and volumetric bone mineral density (vBMD) on quantitative computerized tomography (QCT) analysis compared to closed fractures. PTH((1-34)) treatment in both models led to significant increases in callus BMC and volume as well as trabecular bone volume/total volume (BV/TV), as assessed histologically (p<0.01). In closed fractures, PTH((1-34)) had a robust effect on callus size and strength, with a 60% increase in peak torque (p<0.05). In the open fractures that united and could be tested, PTH((1-34)) treatment also increased peak torque by 49% compared to saline (p<0.05). In conclusion, intermittent PTH((1-34)) produced significant increases in callus size and strength in closed fractures, but failed to increase the rate of union in an open fracture model. In the open fractures that did unite, a muted response to PTH was seen compared to closed fractures. Further research is required to determine if PTH((1-34)) is an appropriate anabolic treatment for open fractures.
间歇性甲状旁腺激素 (PTH) ((1-34)) 在骨质疏松症治疗中已有明确的地位,但在骨修复模型中也显示出有前景的结果。以前的研究主要集中在闭合性骨折模型上,在这些模型中,愈合是确定的。合成代谢治疗的主要临床需求之一是治疗有不愈合风险的开放性和高能骨折。因此,在本研究中,我们比较了 PTH((1-34)) 在开放性和闭合性骨折模型中的治疗效果。108 只雄性 Wistar 大鼠被随机分配接受标准化闭合性骨折或伴有骨膜剥离的开放性截骨术。每组 27 只大鼠接受皮下注射 50 微克/千克 PTH((1-34)),每周 5 天,另 27 只接受生理盐水。在 6 周时采集标本进行力学测试 (n=17) 或组织学分析 (n=10)。在闭合性骨折中,无论采用何种定义,6 周时 PTH((1-34)) 和生理盐水组的愈合率均为 100%。在开放性骨折中,愈合率显著降低 (p<0.05),无论是否接受治疗。在开放性骨折中,机械定义的愈合率在生理盐水组为 10/16 (63%),在 PTH((1-34)) 治疗组为 11/17 (65%)。通过组织学,愈合率在生理盐水组为 3/9 (33%),在 PTH((1-34)) 组为 5/10 (50%)。X 射线摄影术显示,生理盐水组有 13/25 (52%),PTH((1-34)) 组有 15/26 (58%)。与闭合性骨折相比,定量计算机断层扫描 (QCT) 分析显示开放性骨折的骨矿物质含量 (BMC) 和体积骨矿物质密度 (vBMD) 降低。两种模型中,PTH((1-34)) 治疗均导致骨痂 BMC 和体积以及小梁骨体积/总体积 (BV/TV) 显著增加,组织学评估显示差异有统计学意义 (p<0.01)。在闭合性骨折中,PTH((1-34)) 对骨痂大小和强度有显著影响,峰值扭矩增加 60% (p<0.05)。在可测试的愈合的开放性骨折中,与生理盐水组相比,PTH((1-34)) 治疗也使峰值扭矩增加了 49% (p<0.05)。总之,间歇性 PTH((1-34)) 使闭合性骨折的骨痂大小和强度显著增加,但未能提高开放性骨折模型的愈合率。在确实愈合的开放性骨折中,与闭合性骨折相比,PTH 的反应较为温和。需要进一步研究以确定 PTH((1-34)) 是否适合开放性骨折的合成代谢治疗。